Results 151 to 160 of about 29,283 (270)

Understanding the Epigenetic Landscape of Barrett's Esophagus and Esophageal Cancer: A Review of Current Findings, Caveats and Future Directions

Genes, Chromosomes and Cancer, Volume 65, Issue 9, September 2026.
ABSTRACT Esophageal cancer (OC) is currently the eighth most common form of cancer worldwide with a 5‐year survival rate of 10%–20%, with the primary risk factor of esophageal adenocarcinoma (OAC) being the development of Barrett's Esophagus (BO).
Louise Lawless, Trevor Doherty, Carla Surlis, Niamh Gilmartin, Therese M. Murphy   +4 more
wiley   +1 more source

Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review

Head &Neck, Volume 48, Issue 9, Page 2570-2583, September 2026.
ABSTRACT Objective To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. Summary Background Data Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients ...
Nicholas Brian Shannon, Bruce Ashford
wiley   +1 more source

When Blood Speaks Before the Scan: The Role of ctDNA in Real-time CRC Care. [PDF]

Cancer Diagn Progn
Salimiaghdam N, Li E, Liang H.
europepmc   +1 more source

Circulating Tumor DNA and Immune Response Markers for Improved Treatment Outcome Prediction in Diffuse Large B‐Cell Lymphoma: A Scoping Review

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Early identification of refractory disease remains a significant unmet clinical need in patients with diffuse large B‐cell lymphoma (DLBCL). This scoping review was conducted to assess the current knowledge on the use of circulating tumor DNA (ctDNA), either alone or in combination with immune markers, as predictive tools for treatment outcome
Ailin McMahon, Elizabeth J. Ryan, Sarah Dillon, Ruth Clifford   +3 more
wiley   +1 more source

Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large-Cohort Study. [PDF]

MedComm (2020)
You T, Tang H, Yuan M, Song D, Wang C, Ying J, Chen R, Bai C, Cheng Y, Wang Y.   +9 more
europepmc   +1 more source

Detection of Pancreatic Cancer via Specific Metabolite Markers: A Metabolomics Approach

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies worldwide because most patients are diagnosed at advanced stages when curative treatment is no longer feasible. Metabolomics has emerged as a promising strategy for identifying biochemical alterations associated with early tumor development ...
Mohammad Javad Roustaye Gourabi, Mehrangiz Ghafari, Anita Nikoo, Yalda Yarahmadi Saki, Bita Khanbabaei, Masoumeh Khanizadeh, Masoud Kargar, Ali Hashemi, Javad Yasbolaghi Sharahi   +8 more
wiley   +1 more source

Circulating Tumor DNA Genomic Profiling in ²²³Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study. [PDF]

J Nucl Med
Shiota M, Fujiwara M, Sumiyoshi T, Enokida H, Kamba T, Igawa T, Masumori N, Uemura H, Kamoto T, Higashijima K, Mitsunari K, Uemura H, Kobayashi T, Akamatsu S, Tokunaga S, Isoda T, Ishigami K, Eto M.   +17 more
europepmc   +1 more source

ctDNA-Guided Immunotherapy following Radical Cystectomy for Muscle-Invasive Bladder Cancer:Results from the TOMBOLA Trial

Background: Standard treatment of localized muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC), but ∼50% of patients relapse within 2 years.
Pappot, H, Brandt, S B, Lam, G, Agerbæk, M, Jensen, J B, Lindskrog, S V, Dohn, L H, Dyrskjøt, L, Strandgaard, T, Petersen, A C, Fabrin, K, Knudsen, M, Andreasen, T G, Lamy, P, Jensen, N V, Milling, R V, Carus, A; id_orcid, Holt, P S, Körner, S K, Joensen, U N, Hansen, C F, Birkenkamp-Demtröder, K, Nordentoft, I   +22 more
core   +1 more source

Prognostic Factors for Patients Under 45 Undergoing Surgery for Colorectal Liver Metastases: A SEER Population‐Based Study

Journal of Surgical Oncology, Volume 134, Issue 3, Page 322-329, September 2026.
ABSTRACT Background and Objectives Colorectal cancer (CRC) has been on the rise in adults younger than 50. Surgical resection is a potentially curative treatment option for patients with colorectal liver metastases (CRLM). The aim of this study was to describe patient and tumor characteristics associated with disease‐specific survival in young patients
Gabrielle Grob, Fang Fang, Matvey Karpov, Eric Feliberti, Marybeth Hughes, Rachel Burke, Winifred Lo   +6 more
wiley   +1 more source

Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies. [PDF]

Clin Cancer Res
Carleton N, Chang AC, Chen F, Puhalla SL, Foldi J, Waltermire H, Tin A, Cowher MS, Lupinacci K, Diego EJ, Sabih Q, Johnson RR, Malhotra M, Laubenthal A, Gorantla V, Balic M, Bhargava R, Joy M, Freeman T, Bridges C, Kalashnikova E, Rodriguez A, Liu MC, Oesterreich S, Lee AV, McAuliffe PF.   +25 more
europepmc   +1 more source